Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Fluviral (2007-2008) in Adults
NCT00505453Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated) in influenza, sponsored by GSK. Primary endpoint: Immunogenicity of Fluviral influenza vaccine at 21 days. Started Jul 2007; status: completed.
02
Drugs
influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00505453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00505453.